When the AbbVie/Allergan deal was unveiled in June, Allergan investors cheered, as AbbVie’s stock price sank. Analysts also have their doubts. While most viewed it as welcome news for Allergan, dubbing it a “graceful exit” for a “beaten-up name,” they raised multiple folds of concerns for AbbVie, the buyer.
